Drug Profile
Eluforsen - ProQR Therapeutics
Alternative Names: QR 10; QR-010Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator ProQR Therapeutics
- Class Antifibrotics; Oligoribonucleotides
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Cystic-fibrosis in Belgium (Inhalation, Aerosol)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Cystic-fibrosis in Canada (Inhalation, Aerosol)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Cystic-fibrosis in Czech Republic (Inhalation, Aerosol)